Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-10-28
1998-03-31
Barts, Samuel
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514411, A61K 31335
Patent
active
057339252
ABSTRACT:
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.
REFERENCES:
patent: Re32944 (1989-06-01), Harita et al.
patent: 33403 (1861-11-01), Stolle et al.
patent: 3940422 (1976-02-01), Harita et al.
patent: 4070484 (1978-01-01), Harita et al.
patent: 4235988 (1980-11-01), Fildes et al.
patent: 4442119 (1984-04-01), Magarian et al.
patent: 4485096 (1984-11-01), Bell
patent: 4485097 (1984-11-01), Bell
patent: 4555402 (1985-11-01), Matsuda et al.
patent: 4577636 (1986-03-01), Spears
patent: 4826672 (1989-05-01), Milius et al.
patent: 4835002 (1989-05-01), Wolf et al.
patent: 4839155 (1989-06-01), Mccague
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4968350 (1990-11-01), Bindschaedler et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4997652 (1991-03-01), Wong
patent: 5015666 (1991-05-01), Magarian et al.
patent: 5026537 (1991-06-01), Daddona et al.
patent: 5032679 (1991-07-01), Brandley et al.
patent: 5043335 (1991-08-01), Kleinschroth et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5049132 (1991-09-01), Schaffer et al.
patent: 5053033 (1991-10-01), Clarke et al.
patent: 5059166 (1991-10-01), Fischell et al.
patent: 5073633 (1991-12-01), Schroeder et al.
patent: 5093330 (1992-03-01), Caravatti et al.
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5102402 (1992-04-01), Dror et al.
patent: 5112305 (1992-05-01), Barath et al.
patent: 5114719 (1992-05-01), Sabel et al.
patent: 5116864 (1992-05-01), March et al.
patent: 5120535 (1992-06-01), Marquardt et al.
patent: 5140012 (1992-08-01), Mcgovern et al.
patent: 5166143 (1992-11-01), Ondetti et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5176617 (1993-01-01), Fischell et al.
patent: 5180366 (1993-01-01), Woods
patent: 5185260 (1993-02-01), Crissman et al.
patent: 5189046 (1993-02-01), Burch et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5199939 (1993-04-01), Dake et al.
patent: 5208019 (1993-05-01), Hansson et al.
patent: 5208238 (1993-05-01), King
patent: 5213576 (1993-05-01), Abiuso et al.
patent: 5213580 (1993-05-01), Slepian et al.
patent: 5216024 (1993-06-01), Markaverich et al.
patent: 5216126 (1993-06-01), Cox et al.
patent: 5219548 (1993-06-01), Yang et al.
patent: 5221620 (1993-06-01), Purchio et al.
patent: 5226430 (1993-07-01), Spears et al.
patent: 5229495 (1993-07-01), Ichijo et al.
patent: 5232911 (1993-08-01), Vidal et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5238950 (1993-08-01), Clader et al.
patent: 5242397 (1993-09-01), Barath et al.
patent: 5248764 (1993-09-01), Flanagan et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5260224 (1993-11-01), Stossel et al.
patent: 5268358 (1993-12-01), Fretto et al.
patent: 5270047 (1993-12-01), Kauffman et al.
patent: 5280016 (1994-01-01), Conrad et al.
patent: 5280109 (1994-01-01), Miyazono et al.
patent: 5283257 (1994-02-01), Gregory et al.
patent: 5284763 (1994-02-01), Derynk et al.
patent: 5284869 (1994-02-01), Bisaccia et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5288735 (1994-02-01), Trager et al.
patent: 5296492 (1994-03-01), Shiozawa et al.
patent: 5304325 (1994-04-01), Kaufman et al.
patent: 5304541 (1994-04-01), Purchio et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5308862 (1994-05-01), Ohlstein et al.
patent: 5314679 (1994-05-01), Lewis et al.
patent: 5316766 (1994-05-01), Baldus et al.
patent: 5324736 (1994-06-01), Magarin et al.
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328471 (1994-07-01), Slepian
patent: 5332584 (1994-07-01), Scher et al.
patent: 5340925 (1994-08-01), Lioubin et al.
patent: 5346702 (1994-09-01), Na et al.
patent: 5346897 (1994-09-01), King
patent: 5346993 (1994-09-01), Miyazono et al.
patent: 5354562 (1994-10-01), Platz et al.
patent: 5354774 (1994-10-01), Deckelbaum et al.
patent: 5356713 (1994-10-01), Charmot et al.
patent: 5358844 (1994-10-01), Stossel et al.
patent: 5362424 (1994-11-01), Lee et al.
patent: 5364632 (1994-11-01), Benita et al.
patent: 5364843 (1994-11-01), King
patent: 5380716 (1995-01-01), Conrad et al.
patent: 5393763 (1995-02-01), Black et al.
patent: 5395610 (1995-03-01), King et al.
patent: 5444164 (1995-08-01), Purchio et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5460807 (1995-10-01), Cardin et al.
patent: 5468746 (1995-11-01), Casagrande et al.
"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev. L/07/92.
Allemann, et al., "Drug Loaded Poly(lactic acid) Nanoparticles Produced by a Reversible Salting-Out Process: Purification of an Injectable Dosage Form", Eur. J. Pharm. Biopharm., 39, 13-18 (1993).
Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor .beta.-interluekin and .beta.2-micorglobulin Plasma Levels", Kidney International, 40, 1110-1117 (1991).
Assoian, et al., "Type .beta. Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells", J. Cell. Biol., 102, 1217-1223 (Apr. 1986).
Attwood, D., et al., "A Light Scattering Study on Oil-in-Water Microemulsions," International Journal of Pharmaceutics, 52, 165-171 (1989).
Bagdade, J.D., et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).
Bamburg, et al., "Biological and Biochemical Actions of Trichothecene Mycotoxins", In: Progress in Molecular and Subcellular Biology, vol. 8, F.E. Hahn et al., (eds.), Springer-Verlag, Berlin, pp. 41-110 (1983).
Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", JACC, 13, 252A (Feb. 1989).
Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels", Breast Cancer Res. and Treatment, 12, 307-310 (1988).
Bogyo, et al., "Cytochalasin-B-induced Immunosuppression of Murine Allogenic Anti-Tumor Response and the Effect of Recombinant Human Interleukin-2", Cancer Immunol. Immunother., 32, 400-405 (1991).
Bousquet, et al., "Effects of Cytochalsin B in Culture and in Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma", Cancer Res., 50, 1431-1439 (Mar. 1, 1990).
Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs", J. Urology, 130, 1208-1210 (Dec. 1983).
Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988).
Butta, A., et al., "Induction of Transforming Growth Factor Beta 1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment", Cancer, Res. 52, 4261-4164 (1992).
Chaldakov, et al., "Cyclic AMP-and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: its Cytopharmacological Characterization", Cell Tissue Res., 255, 434-442 (1989).
Chandler, et al., "Pyrrolidino-4-idotamoxifen and 4-idotamamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", Cancer Res., 51, 5851-5858 (Nov. 1, 1991).
Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from
Anderson Peter G.
Grainger David J.
Klein Richard A.
Kunz Lawrence L.
Metcalfe James C.
Barts Samuel
NeoRx Corporation
LandOfFree
Therapeutic inhibitor of vascular smooth muscle cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic inhibitor of vascular smooth muscle cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic inhibitor of vascular smooth muscle cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-52427